Inovio Pharmaceuticals
106 hedge funds and large institutions have $133M invested in Inovio Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 33 reducing their positions, and 21 closing their positions.
42% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $716K
0.05% less ownership
Funds ownership: 2.3% → 2.25% (-0.05%)
6% less capital invested
Capital invested by funds: $142M → $133M (-$9.09M)
15% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 33
15% less funds holding
Funds holding: 125 → 106 (-19)
62% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$35.3M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.51M |
| 4 |
TCM
Tanaka Capital Management
New York
|
+$644K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$459K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.98M |
| 2 |
Morgan Stanley
New York
|
-$1.21M |
| 3 |
Millennium Management
New York
|
-$1.06M |
| 4 |
Citigroup
New York
|
-$874K |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
-$861K |
INO Hedge Fund Activity: Q1 2017 in Review
106 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2017, worth a combined $133M — down 6.4% from $142M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of INO and 8 opened new positions — a net loss of 13 holders — while 33 trimmed existing stakes and 28 added.
The largest buyer was BlackRock, adding an estimated $35.3M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.98M sold.
- 106 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2017, down from 125 in Q4 2016.
- Funds reported $133M of Inovio Pharmaceuticals stock for Q1 2017, down 6.4% quarter-over-quarter.
- 8 funds opened new Inovio Pharmaceuticals positions in Q1 2017 and 21 closed out, a net change of -13 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $35.3M added.
- The largest Inovio Pharmaceuticals seller in Q1 2017 was Susquehanna International Group, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2017.